在心力衰竭中使用SGLT2抑制剂,并保留喷射分数
Mohammed Faluk1, Abdirahman Wardhere2, Ravi Thakker1
1Department of Internal Medicine, Division of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX 77550.
Current problems in cardiology
|January 6, 2024
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂在用保存喷射分数 (HFpEF) 治疗心力衰竭方面表现有前途. 本综述检查了它们对减少HFpEF患者住院和死亡率的影响.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 心力衰竭 (HF) 是一个重要的全球健康负担.
- 以左心室喷射率 (LVEF) ≥50%定义的保存喷射率 (HFpEF) 的心力衰竭占HF病例的一半以上,并且正在增加.
- 从历史上看,HFpEF的治疗选择有限,影响住院和死亡率.
研究的目的:
- 对HFpEF中的-葡萄糖共运输体2 (SGLT2) 抑制剂的当前文献和临床试验进行审查.
- 评估SGLT2抑制剂在管理HFpEF方面的疗效.
- 探索SGLT2抑制剂在减少HFpEF患者不良后果方面的潜力.
主要方法:
- 相关临床试验和研究的文献搜索.
- 来自随机对照试验的数据分析,这些试验调查了HFpEF中的SGLT2抑制剂.
- 关于SGLT2抑制剂对HFpEF结果的影响的综合发现.
主要成果:
- -葡萄糖携带载体2 (SGLT2) 抑制剂在高高压血压发作患者中显示出显著的益处.
- 这些好处包括减少心力衰竭住院和心血管死亡率.
- 新出现的证据支持SGLT2抑制剂作为HFpEF的关键治疗类.
结论:
- SGLT2 抑制剂代表了HFpEF治疗的突破.
- 需要进一步的研究和临床应用,以优化它们的使用.
- 这些药物为改善日益增长的HFpEF人口的预后提供了新的途径.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
433
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
01:22Heart Failure Drugs: Diuretics
388
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
388
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:23Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K